{"title": "Hepatitis t\u00f3xica tras tratamiento con flutamida", "author": "L Bengoechea Gallastegui; A Vita Garay; A Castiella Eguzkiza; J F Egido Arroyo", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676060/", "hostname": "ncbi.nlm.nih.gov", "description": "La flutamida es un antiandr\u00f3geno no esteroideo generalmente bien tolerado, usado para el tratamiento del c\u00e1ncer de pr\u00f3stata[1] . Los efectos secundarios m\u00e1s frecuentes de la flutamida son n\u00e1useas, diarrea y ginecomastia[2] ...", "sitename": "PubMed Central (PMC)", "date": "2005-06-22", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Learn more:\n[PMC Disclaimer](/pmc/about/disclaimer/)| [PMC Copyright Notice](/pmc/about/copyright/) [10.1157/13076603](//doi.org/10.1157%2F13076603) [15989835](https://pubmed.ncbi.nlm.nih.gov/15989835)\nHepatitis t\u00f3xica tras tratamiento con flutamida\nAbstract\nIntroducci\u00f3n\nLa flutamida es un antiandr\u00f3geno no esteroideo generalmente bien tolerado, usado para el tratamiento del c\u00e1ncer de pr\u00f3stata1. Los efectos secundarios m\u00e1s frecuentes de la flutamida son n\u00e1useas, diarrea y ginecomastia2. La incidencia de hepatotoxicidad asociada a flutamida es muy baja y no excede el 0,18%3. Tambi\u00e9n se han descrito casos de toxicidad hep\u00e1tica por flutamida en mujeres tratadas por hirsutismo4.\nCaso cl\u00ednico\nA continuaci\u00f3n presentamos el caso de un var\u00f3n de 68 a\u00f1os con antecedents de carcinoma de pr\u00f3stata, prostatectomizado en 2002 con 30 semanas de radioterapia y en tratamiento con flutamida (Prostacur\u00ae), hepatitis B hace 11 a\u00f1os con HBsAg positivo y neumon\u00eda, que acude a nuestra consulta por hipertransaminasemia. No hay factores de riesgo cardiovasculares ni h\u00e1bitos t\u00f3xicos. En el momento en el que el paciente acudi\u00f3 a nuestra consulta presentaba unos valores de GOT 1.309 U/l (0-40 U/l), GPT 1.474 U/l (0-40 U/l), GGT 540 U/l (10-50 U/l), ferritina 3.589 ng/ml (15-200 ng/ml) y alfafetoprote\u00edna 11,5 U/ml (0-7 U/ml). La ecograf\u00eda y la tomograf\u00eda computarizada abdominales fueron normales. Un estudio con PCR del ADN-VHB mostraba unas cifras de 10.100 gen/ml. La serolog\u00eda de la hepatitis presentaba los siguientes resultados: HBsAg positivo, anti-HBc positivo, HBe-Ag negativo y antiHBe positivo. Una semana despu\u00e9s de la retirada del f\u00e1rmaco los valores de GOT, GPT y GGT descendieron a 50, 49 y 319 U/l, respectivamente, lo cual, tras descartar hepatotoxicidad por etanol, alteraciones hepatobiliares en ecograf\u00eda, enfermedades autoinmunes por dep\u00f3sitos de hierro y cobre, infecci\u00f3n reciente por virus de hepatitis A, B y C y otras causas etiol\u00f3gicas, apoya el diagn\u00f3stico de hepatitis t\u00f3xica tras tratamiento con flutamida seg\u00fan las escalas diagn\u00f3sticas de hepatotoxicidad por f\u00e1rmacos de Mar\u00eda y Victorino, 19975 y la CIOMS, 19936. Reafirma tambi\u00e9n este diagn\u00f3stico la pr\u00e1cticamente completa resoluci\u00f3n de la alteraci\u00f3n anal\u00edtica al mes de suspender el tratamiento con flutamida, quedando las transaminasas normales.\nDiscusi\u00f3n y conclusiones\nLas manifestaciones cl\u00ednicas de la hepatitis inducida por flutamida incluyen elevaci\u00f3n asintom\u00e1tica de transaminasas, hepatitis t\u00f3xica y hepatitis colest\u00e1sica con gran elevaci\u00f3n de la fosfatasa alcalina s\u00e9rica y r-GGT2. Los pacientes normalmente retornan a la normalidad tras la retirada del f\u00e1rmaco, pero se han descrito casos de mortalidad tras s\u00edndrome hepatorrenal2, encefalopat\u00eda hep\u00e1tica y hepatitis fulminantes7.\nLa anatom\u00eda patol\u00f3gica de estos pacientes muestra una necrosis difusa severa de los hepatocitos. Se han descrito en numerosas ocasiones casos con patr\u00f3n de colestasis y necrosis focal, pero s\u00f3lo unos pocos con inflamaci\u00f3n portal y necrosis focal.\nEl mecanismo por el cual la flutamida produce hepatotoxicidad no es bien conocido, pero podr\u00edan estar implicadas disfunciones mitocondriales1.\nEl riesgo de presentar un fallo hep\u00e1tico, encefalopat\u00eda hep\u00e1tica e incluso la muerte debido a la toma de flutamida deber\u00eda ser tenido en cuenta a la hora de iniciar este tratamiento, por lo que es necesario un control estricto de los valores de enzimas hep\u00e1ticas durante el tratamiento, sobre todo en pacientes como el nuestro con una hepatopat\u00eda previa. Ser\u00eda recomendable advertir al paciente de que consulte inmediatamente en caso de iniciar un cuadro de n\u00e1useas, v\u00f3mitos, fatiga e ictericia en el transcurso del tratamiento con flutamida para prevenir la posible aparici\u00f3n de estos trastornos.\nBibliograf\u00eda\n[PubMed](https://pubmed.ncbi.nlm.nih.gov/14971714)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ann+Ital+Med+Int&title=Flutamide-associated+acute+liver+failure&author=G.+Famularo&author=C.+De+Simone&author=G.+Minisola&author=G.C.+Nicotra&volume=18&publication_year=2003&pages=250-253&pmid=14971714&)] [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Yonsei+Med+J&title=A+case+of+flutamide-induced+acute+cholestatic+hepatitis&author=L.+Hong+Woo&author=C.+Jun+Pyo&author=L.+Kwi+Soon&author=K.+Kyung+Chul&author=L.+Kwan+Sik&volume=37&publication_year=1996&pages=225-229&pmid=8826789&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/9324896)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Actas+Urol+Esp&title=Liver+failure+caused+by+flutamide&author=P.L.+Guzm\u00e1n+Mart\u00ednez-Valls&author=R.+Ferrero+Doria&author=J.P.+Morga+Egea&author=M.+Tomas+Ros&author=J.L.+Rico&volume=21&publication_year=1997&pages=278-282&pmid=9324896&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/8110241)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ann+Intern+Med&title=Hepatotoxicity+complicating+flutamide+treatment+of+hirsutism&author=C.+Wallace&author=E.A.+Lalor&author=C.L.+Chik&volume=119&publication_year=1993&pages=1150&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/9303497)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Hepatology&title=Development+and+validation+OR+a+clinical+scale+for+the+diagnosis+of+drug-induced+hepatitis&author=V.A.J.+Mar\u00eda&author=R.M.M.+Victorino&volume=26&publication_year=1997&pages=664-669&pmid=9303497&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/8229110)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Ckin+Epidemiol&title=Causality+assessment+of+adverse+drug+reactions+to+drugs+I.+A+novel+method+based+on+the+conclusions+of+international+consensus+meetings:+application+to+drug-induced+liver+injuries&author=G.+Danan&author=C.+B\u00e8nichou&volume=46&publication_year=1993&pages=1323-1330&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/9493166)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Med+Clin+(Barc)&title=Fulminant+hepatitis+associated+with+treatment+with+flutamide&author=P.+Garc\u00eda-Gasco&author=C.+Morata+Aldea&author=A.+Segura+Huertas&author=J.+Aparicio+Urtasun&volume=109&publication_year=1997&pages=820&)]", "language": null, "image": "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0", "pagetype": "article", "links": ["#main-content", "https://www.ncbi.nlm.nih.gov/", "https://account.ncbi.nlm.nih.gov", "/myncbi/", "/myncbi/collections/bibliography/", "/account/settings/", "/account/signout/", "https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys", "https://www.ncbi.nlm.nih.gov", "/myncbi/", "#maincontent", "#", "/pmc/", "https://www.ncbi.nlm.nih.gov/pmc/advanced", "/pmc/about/userguide/", "/pmc/journals/", "/pmc/journals/3749/", "/pmc/issues/369158/", "/pmc/articles/PMC7676060/?report=reader", "/pmc/articles/PMC7676060/pdf/main.pdf", "#", "https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7676060%2F&text=Hepatitis%20t%F3xica%20tras%20tratamiento%20con%20flutamida", "https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7676060%2F", "/pmc/journals/", "/pmc/journals/3749/", "/pmc/issues/369158/", "/pmc/about/disclaimer/", "/pmc/about/copyright/", "//doi.org/10.1157%2F13076603", "https://pubmed.ncbi.nlm.nih.gov/15989835", "https://pubmed.ncbi.nlm.nih.gov/?term=Bengoechea%20Gallastegui%20L%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Vita%20Garay%20A%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Castiella%20Eguzkiza%20A%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Egido%20Arroyo%20J%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Bengoechea%20Gallastegui%20L%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Vita%20Garay%20A%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Castiella%20Eguzkiza%20A%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Egido%20Arroyo%20J%5BAuthor%5D", "#", "#", "/pmc/about/disclaimer/", "/pmc/about/copyright/", "https://pubmed.ncbi.nlm.nih.gov/14971714", "https://scholar.google.com/scholar_lookup?journal=Ann+Ital+Med+Int&title=Flutamide-associated+acute+liver+failure&author=G.+Famularo&author=C.+De+Simone&author=G.+Minisola&author=G.C.+Nicotra&volume=18&publication_year=2003&pages=250-253&pmid=14971714&", "https://scholar.google.com/scholar_lookup?journal=Yonsei+Med+J&title=A+case+of+flutamide-induced+acute+cholestatic+hepatitis&author=L.+Hong+Woo&author=C.+Jun+Pyo&author=L.+Kwi+Soon&author=K.+Kyung+Chul&author=L.+Kwan+Sik&volume=37&publication_year=1996&pages=225-229&pmid=8826789&", "https://pubmed.ncbi.nlm.nih.gov/9324896", "https://scholar.google.com/scholar_lookup?journal=Actas+Urol+Esp&title=Liver+failure+caused+by+flutamide&author=P.L.+Guzm\u00e1n+Mart\u00ednez-Valls&author=R.+Ferrero+Doria&author=J.P.+Morga+Egea&author=M.+Tomas+Ros&author=J.L.+Rico&volume=21&publication_year=1997&pages=278-282&pmid=9324896&", "https://pubmed.ncbi.nlm.nih.gov/8110241", "https://scholar.google.com/scholar_lookup?journal=Ann+Intern+Med&title=Hepatotoxicity+complicating+flutamide+treatment+of+hirsutism&author=C.+Wallace&author=E.A.+Lalor&author=C.L.+Chik&volume=119&publication_year=1993&pages=1150&", "https://pubmed.ncbi.nlm.nih.gov/9303497", "https://scholar.google.com/scholar_lookup?journal=Hepatology&title=Development+and+validation+OR+a+clinical+scale+for+the+diagnosis+of+drug-induced+hepatitis&author=V.A.J.+Mar\u00eda&author=R.M.M.+Victorino&volume=26&publication_year=1997&pages=664-669&pmid=9303497&", "https://pubmed.ncbi.nlm.nih.gov/8229110", "https://scholar.google.com/scholar_lookup?journal=J+Ckin+Epidemiol&title=Causality+assessment+of+adverse+drug+reactions+to+drugs+I.+A+novel+method+based+on+the+conclusions+of+international+consensus+meetings:+application+to+drug-induced+liver+injuries&author=G.+Danan&author=C.+B\u00e8nichou&volume=46&publication_year=1993&pages=1323-1330&", "https://pubmed.ncbi.nlm.nih.gov/9493166", "https://scholar.google.com/scholar_lookup?journal=Med+Clin+(Barc)&title=Fulminant+hepatitis+associated+with+treatment+with+flutamide&author=P.+Garc\u00eda-Gasco&author=C.+Morata+Aldea&author=A.+Segura+Huertas&author=J.+Aparicio+Urtasun&volume=109&publication_year=1997&pages=820&", "/pmc/articles/PMC7676060/?report=reader", "/pmc/articles/PMC7676060/pdf/main.pdf", "#", "https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7676060%2F&text=Hepatitis%20t%F3xica%20tras%20tratamiento%20con%20flutamida", "https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7676060%2F", "#", "https://twitter.com/ncbi", "https://www.facebook.com/ncbi.nlm", "https://www.linkedin.com/company/ncbinlm", "https://github.com/ncbi", "https://ncbiinsights.ncbi.nlm.nih.gov/", "https://www.nlm.nih.gov/socialmedia/index.html", "https://twitter.com/NLM_NIH", "https://www.facebook.com/nationallibraryofmedicine", "https://www.youtube.com/user/NLMNIH", "https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323", "https://www.nlm.nih.gov/web_policies.html", "https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office", "https://www.hhs.gov/vulnerability-disclosure-policy/index.html", "https://support.nlm.nih.gov/", "https://www.nlm.nih.gov/accessibility.html", "https://www.nlm.nih.gov/careers/careers.html", "//www.nlm.nih.gov/", "https://www.nih.gov/", "https://www.hhs.gov/", "https://www.usa.gov/"]}